Findings

What do systematic reviews say?

480 questions · 484 findings · 52 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 114 · 23.6%GRADE not reported 24 · 5%Very low 33 · 6.8%Low 145 · 30%Moderate 116 · 24%High 52 · 10.7%

Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + DMARDs/biologic

ACR50% improvement criteria · patients with rheumatoid arthritis

Tocilizumab 8 mg/kg + MTX/DMARD leads to higher ACR50% improvement criteria compared with placebo + MTX/DMARD (high certainty).

1 finding from 1 review

Tocilizumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 3.17 [2.72, 3.67]
4 studies · 2063 participants
High

Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + DMARDs/biologic

DAS (low or remission) · patients with rheumatoid arthritis

Tocilizumab 8 mg/kg + MTX/DMARD leads to higher DAS Remission defined as DAS28 <2.6 compared with placebo + MTX/DMARD (high certainty).

1 finding from 1 review

Tocilizumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 8.74 [6.26, 11.8]
4 studies · 1946 participants
High

Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + DMARDs/biologic

HAQ improvement of >0.3 or MHAQ decrease of >0.22 (changes exceeding MCID) · patients with rheumatoid arthritis

Tocilizumab 8 mg/kg + MTX/DMARD leads to higher HAQ improvement of >0.3 or MHAQ decrease of >0.22 (changes exceeding… compared with placebo + MTX/DMARD (high certainty).

1 finding from 1 review

Tocilizumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 1.79 [1.62, 1.94]
1 study · 1220 participants
High

Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + DMARDs/biologic

Serious adverse events · patients with rheumatoid arthritis

Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in serious Adverse Events compared with placebo + MTX/DMARD (moderate certainty).

1 finding from 1 review

Tocilizumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 1.17 [0.83, 1.64]
3 studies · 1961 participants
Moderate

Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + DMARDs/biologic

Acceptability: total withdrawals · patients with rheumatoid arthritis

Tocilizumab 8 mg/kg + MTX/DMARD probably leads to lower total withdrawals compared with placebo + MTX/DMARD (moderate certainty).

1 finding from 1 review

Tocilizumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 0.61 [0.49, 0.77]
4 studies · 2064 participants
Moderate

Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + DMARDs/biologic

Withdrawals due to adverse events · patients with rheumatoid arthritis

Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in withdrawals due to Adverse events compared with placebo + MTX/DMARD (high certainty).

1 finding from 1 review

Tocilizumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 1.43 [0.95, 2.12]
4 studies · 2064 participants
High

Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + DMARDs/biologic

Radiographic progression · patients with rheumatoid arthritis

1 finding from 1 review

Tocilizumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 4 participants
GRADE not reported

Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX

ACR 50% improvement · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX leads to higher ACR50 compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 2.57 [1.34, 4.94]
4 studies · 919 participants
High

Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX

DAS (low or remission) · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX leads to higher disease activity (DAS Remission) compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 5.12 [1.67, 15.66]
4 studies · 919 participants
High

Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX

Physical function · patients with rheumatoid arthritis

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 308 participants
High

Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX

Adverse events · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX showed no clear difference in adverse Events compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 1.05 [0.93, 1.18]
4 studies · 918 participants
High

Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX

Serious adverse events · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX showed no clear difference in serious Adverse Events compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 1.05 [0.62, 1.78]
4 studies · 918 participants
High

Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX

Study Withdrawals · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX leads to lower all Withdrawals compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 0.5 [0.31, 0.81]
4 studies · 917 participants
High

Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX

Withdrawals due to adverse events · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX showed no clear difference in withdrawals due to Adverse Events compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 0.56 [0.24, 1.29]
3 studies · 599 participants
High

Summary of findings: 5 mg/day vs placebo

Benefits · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Function ‐ not measured · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Harms · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Headache · rotator cuff disease

Summary of findings: 1.25 mg/day plus rehabilitation showed no clear difference in headache ( compared with placebo plus rehabilitation (low certainty).

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
RR 1.73 [0.92, 3.24]
1 study · 53 participants
Low

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Rash · rotator cuff disease

Summary of findings: 1.25 mg/day plus rehabilitation showed no clear difference in rash ( compared with placebo plus rehabilitation (low certainty).

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
RR 3.12 [0.35, 28.06]
1 study · 53 participants
Low

Summary of findings: 5 mg/day vs placebo

Pain intensity (0‐10cm visual analogue scale) · rotator cuff disease

1 finding from 1 review

Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low